Arnab Chakravarti MD

Arnab Chakravarti MD
ChairCollege of Medicinechakravarti.7@osu.edu
080B James Cancer Hosp & Res Inst 300 W 10th Avenue Columbus Ohio 43210
Phone:614-293-3247Fax:
  • Translational Therapeutics

Research Description

Dr. Chakravarti’s Research Group is comprised of multiple faculty members and has a primary focus of investigating the molecular, genetic, and epigenetic mechanisms of treatment resistance in human tumors and developing strategies to circumvent this resistance in the clinic. A major focus of the group is on signal transduction pathways, specifically the PI3K/AKT pathway, in glioblastoma and prostate cancer. Dr. Chakravarti is an internationally-recognized cancer researcher and has received continuous federal funding since 1999 to support his research activities.

Current Publications

  • Kroonen J, Bredel M, Nguyen-Khac M, Deprez M, Schoysman L, Poulet C, Chakravarti A, Kim H, Scholtens D, Seute T, Rogister B, Bours V, Robe PA, Artesi MConnexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.Neuro Oncol in press 8/25/2014
  • Wojton J, Meisen WH, Jacob NK, Thorne AH, Hardcastle J, Denton N, Chu Z, Dmitrieva N, Marsh R, Van Meir EG, Kwon CH, Chakravarti A, Qi X, Kaur BSapC-DOPS-induced lysosomal cell death synergizes with TMZ in glioblastoma.Oncotarget in press 7/17/2014
  • Woods G, Sebastian N, Fabian D, Kaplon R, Hammond S, Palanichamy K, Chakravarti A, Houghton PJ, Singh M, Leasure JM, Chronowski C, Geier B, Bondra K, Duan W, Hensley LA, Villalona-Calero M, Li N, Vergis AM, Kurmasheva RT, Shen CFANCD2 is a potential therapeutic target and biomarker in alveolar rhabdomyosarcoma harboring the PAX3-FOXO1 fusion gene.Clin Cancer Res 20 3884-95 7/15/2014
  • Guo Deliang, Geng F, Aggarwal R, Liu J, Yoo JY, Guo Q, Guo JY, Hurwitz B, Ru P, Cheng C, Joshi K, Ichiro Nakano, Kaur Balveen, Chakravarti ArnabInterplay of lipid droplets and autophagy regulates glioblastoma survival.Neuro Oncol 16 Suppl 3 iii9 7/1/2014
  • Bredel M, Ferrarese R, Harsh GR 4th, Yadav AK, Bug E, Maticzka D, Reichardt W, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu IL, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, Elverfeldt DV, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti Arnab, Rich JN, Carro MSAberrant splicing of a brain-enriched alternative exon eliminates tumor suppressor function and promotes oncogene function during brain tumorigenesis.Neuro Oncol 16 Suppl 3 iii19-iii20 7/1/2014
  • Hadler M, Scholtens DM, Yu IL, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS, Bredel M, Ferrarese R, Harsh GR 4th, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai F, Kim HLineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression.J Clin Invest 124 2861-76 7/1/2014
  • Martin LK, Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan J, Bell EH, Wojton J, Jacob NK, Chakravarti A, Nowicki MO, Wu X, Lapalombella R, Datta J, Yu B, Gordon K, Haseley A, Patton JT, Smith PL, Ryu J, Zhang X, Yan F, Alinari L, Lustberg ME, Mo X, Marcucci G, Nuovo G, Kwon CH, Byrd JC, Chiocca EA, Li C, Sif S, Jacob S, Lawler S, Kaur B, Baiocchi RAGenetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.Cancer Res 74 1752-65 3/15/2014
  • Chakravarti AEditorial on "targeting Wee1 for the treatment of pediatric high-grade gliomas".Neuro Oncol 16 325 3/1/2014
  • Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MPA randomized trial of bevacizumab for newly diagnosed glioblastoma.N Engl J Med 370 699-708 2/20/2014
  • Rong Y, Walston S, Welliver MX, Chakravarti A, Quick AMImproving intra-fractional target position accuracy using a 3D surface surrogate for left breast irradiation using the respiratory-gated deep-inspiration breath-hold technique.PLoS One 9 e97933 1/1/2014
  • Chaswal V, Weldon M, Gupta N, Chakravarti A, Rong YCommissioning and comprehensive evaluation of the ArcCHECK cylindrical diode array for VMAT pretreatment delivery QA.J Appl Clin Med Phys 15 4832 1/1/2014
  • Guo D, Bell EH, Mischel P, Chakravarti ATargeting SREBP-1-driven lipid metabolism to treat cancer.Curr Pharm Des 20 2619-26 1/1/2014
  • Geiger KD, von Kummer R, Cerhova J, Chakravarti A, Krex D, Schackert G, Juratli TA, Engellandt K, Lautenschlaeger TIs there pseudoprogression in secondary glioblastomas?Int J Radiat Oncol Biol Phys 87 1094-9 12/1/2013
  • Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP, Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan ADose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial.J Clin Oncol 31 4085-91 11/10/2013
  • Chettiar SN, Cooley JV, Park IH, Bhasin D, Chakravarti A, Li PK, Li C, Jacob NKDesign, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle.Bioorg Med Chem Lett 23 5429-33 10/1/2013
  • Meng W, Ye Z, Cui R, Perry J, Dedousi-Huebner V, Huebner A, Wang Y, Li B, Volinia S, Nakanishi H, Kim T, Suh SS, Ayers LW, Ross P, Croce CM, Chakravarti A, Jin VX, Lautenschlaeger TMicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma.Clin Cancer Res 19 5423-33 10/1/2013
  • Chakravarti A, Bhargava RLymphangioma circumscriptum of the tongue in children: successful treatment using intralesional bleomycin.Int J Pediatr Otorhinolaryngol 77 1367-9 8/1/2013
  • Shirai K, Mizui T, Suzuki Y, Okamoto M, Hanamura K, Yoshida Y, Hino M, Noda SE, Al-jahdari WS, Chakravarti A, Shirao T, Nakano TX irradiation changes dendritic spine morphology and density through reduction of cytoskeletal proteins in mature neurons.Radiat Res 179 630-6 6/1/2013
  • Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti ABladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival.Oncologist 18 685-6 6/1/2013
  • Carbone DP, Chakravarti AFrom the guest editors: management of locally advanced lung cancer.Cancer J 19 199 5/1/2013
  • Guo D, Bell EH, Chakravarti ALipid metabolism emerges as a promising target for malignant glioma therapy.CNS Oncol 2 289-99 5/1/2013
  • Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, Schultz CJ, Choucair A, Dolled-Filhart M, Christiansen J, Gustavson M, Molinaro A, Mischel P, Dicker AP, Bredel M, Mehta MRTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.Int J Radiat Oncol Biol Phys 85 1206-11 4/1/2013
  • Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ Jr, Bentzen SM, Okunieff P, Coleman CN, Dicker APNCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.J Natl Cancer Inst 105 11-24 1/2/2013
  • Ru P, Williams TM, Chakravarti A, Guo DTumor metabolism of malignant gliomas.Cancers (Basel) 5 1469-84 1/1/2013
  • Jacob NK, Cooley JV, Yee TN, Jacob J, Alder H, Wickramasinghe P, Maclean KH, Chakravarti AIdentification of sensitive serum microRNA biomarkers for radiation biodosimetry.PLoS One 8 e57603 1/1/2013
  • Meng W, McElroy JP, Volinia S, Palatini J, Warner S, Ayers LW, Palanichamy K, Chakravarti A, Lautenschlaeger TComparison of microRNA deep sequencing of matched formalin-fixed paraffin-embedded and fresh frozen cancer tissues.PLoS One 8 e64393 1/1/2013
  • Lautenschlaeger T, Perry J, Peereboom D, Li B, Ibrahim A, Huebner A, Meng W, White J, Chakravarti AIn vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.Radiat Oncol 8 246 1/1/2013
  • Waters JD, Sanchez C, Sahin A, Futalan D, Gonda DD, Scheer JK, Akers J, Palanichamy K, Waterman P, Chakravarti A, Weissleder R, Morse B, Marsh N, Furfine E, Chen CC, Carvajal I, Carter BSCT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy.J Neurooncol 110 37-48 10/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu